Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Radiation Therapy
100%
Chemoradiotherapy
96%
Overall Survival
82%
Rectum Cancer
62%
Abdominal Cancer
61%
Chemotherapy
57%
Malignant Neoplasm
43%
Anal Cancer
39%
Neoplasm
34%
Recurrent Disease
33%
Stomach Adenocarcinoma
30%
Diseases
28%
Pancreas Cancer
27%
Adenocarcinoma
27%
Intensity Modulated Radiation Therapy
27%
Squamous Cell Carcinoma
25%
Pancreas Adenocarcinoma
22%
Cancer
22%
Chemoradiation Therapy
21%
Radiation Oncology
20%
Pelvis
17%
Metastatic Carcinoma
17%
Clinical Trial
17%
Re-Irradiation
15%
Gastrectomy
15%
Neoadjuvant Therapy
15%
Capecitabine
15%
Computer Assisted Tomography
14%
Hazard Ratio
14%
Survival Rate
13%
Rectum Carcinoma
13%
Tumor
13%
Oncology
12%
Progression Free Survival
12%
Stereotactic Body Radiation Therapy
12%
Systemic Therapy
12%
Cholangiocarcinoma
12%
Anal Canal
11%
Fluorouracil
11%
Quality of Life
11%
Lymph Node
10%
Hodgkin's Lymphoma
10%
Anus
10%
Treatment Planning
10%
Acute Toxicity
10%
Cisplatin
9%
Colorectal Carcinoma
9%
Phase II Trials
8%
Hepatocellular Carcinoma
8%
Proportional Hazards Model
8%
Keyphrases
Overall Survival
54%
Chemoradiation
50%
Gastric Cancer
42%
Rectal Cancer
40%
Anal Cancer
38%
Radiation Therapy
32%
Gastric Adenocarcinoma
31%
Radiotherapy
28%
Chemotherapy
27%
Preoperative Therapy
25%
Preoperative Chemoradiation
22%
Intensity-modulated Radiation Therapy
19%
Re-irradiation
16%
Tumor
16%
Capecitabine
14%
95% Confidence Interval
14%
Gastrectomy
14%
Radiation Oncology
13%
Locally Advanced Rectal Cancer
12%
Resection
12%
Systemic Therapy
12%
Hazard Ratio
12%
Gastric Cancer Patients
12%
Acute Toxicity
11%
Median Overall Survival
11%
Squamous Cell Carcinoma of the Anus
11%
Metastatic Disease
11%
Local Control
11%
Anal Canal Carcinoma
11%
Progression-free Survival
11%
Pathological Complete Response
11%
United States
11%
Pancreatic Ductal Adenocarcinoma
10%
Cisplatin
10%
Locoregional Recurrence
10%
Rectal Adenocarcinoma
10%
Clinical Trials
10%
5-fluorouracil (5-FU)
9%
Dose Escalation
9%
Combined Modality Therapy
9%
Liver
9%
Gastroesophageal Adenocarcinoma
9%
Concurrent Chemotherapy
9%
ACR Appropriateness Criteria
9%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Local Recurrence
9%
Adenocarcinoma
8%
Stereotactic Body Radiation Therapy
8%
Disease-free Survival
8%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
8%